Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany
PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin ...
X4 Pharmaceuticals announces strategic restructuring, reduces headcount by 30%
X4 Pharmaceuticals (XFOR) announced a restructuring of its workforce and capital spending to focus efforts on advancing mavorixafor to treat ...
Yale Daily News1d
First FDA-approved non-addictive painkiller has Yale roots
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
GlobalData on MSN2d
Cumberland Pharmaceuticals reports data from trial of ifetroban for DMD
High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.
Rockville's OS Therapies acquires rights to key drugs, eyes FDA approval for cancer therapy
A Rockville immunotherapy company struck an $8 million deal to take back ownership of the drug candidates it’s been licensing ...
D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder
D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
Wall Street Journal6d
Vertex Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...